UCB Trading (Shanghai) Co., Ltd.

Primary objective: To compare the efficacy of Bimekizumab administered subcutaneously for 16 weeks with placebo in the treatment of moderate to severe plaque PSO study subjects. Secondary objectives: To evaluate the efficacy of Bimekizumab compared with placebo at 4 weeks: achieving PASI75 response; To evaluate the efficacy of Bimekizumab compared with placebo at 16 weeks: achieving complete clearance (PASI100); To evaluate the effect of Bimekizumab compared with placebo at 16 weeks on pruritus, pain and scaling as assessed by PSD (P-SIM) response; To evaluate the safety of Bimekizumab during the 16-week treatment period.

To evaluate the long-term safety and tolerability of Staccato alprazolam To evaluate the probability of success of repeat treatment with Staccato alprazolam (for treatment of seizures occurring within the first 6 months [up to 10 seizures treated]) To evaluate the probability of success of repeat treatment with Staccato alprazolam without seizure recurrence within 2 hours (for treatment of seizures occurring within the first 6 months [up to 10 seizures treated]) To evaluate the long-term pulmonary safety of Staccato alprazolam

Comparison of the rapid and successful termination of seizures within 90 seconds after IMP administration between a single dose of Staccato alprazolam and placebo Comparison of the rapid and successful termination of seizures within 90 seconds after IMP administration between a single dose of Staccato alprazolam and placebo, and no recurrence of seizures within 2 hours after IMP administration Comparison of the rapid and successful termination of seizures within 90 seconds after IMP administration between a single dose of Staccato alprazolam and placebo, and no recurrence of seizures within 4 hours after IMP administration Comparison of the rapid and successful termination of seizures within 90 seconds after IMP administration between a single dose of Staccato alprazolam and placebo, and no recurrence of seizures within 6 hours after IMP administration Comparison of the time from IMP administration to termination of treated seizures between Staccato alprazolam and placebo Evaluation of the pulmonary safety of a single dose of Staccato alprazolam compared to placebo Comparison of the incidence of subsequent seizures within 2 hours after IMP administration between Staccato alprazolam and placebo